The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Sustained hippocampal IL-1β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology
Open accessAbstract
Neuroinflammation is a conspicuous feature of Alzheimer disease (AD) pathology and is thought to contribute to the ultimate neurodegeneration that ensues. IL-1 beta has emerged as a prime candidate underlying this response. Here we describe a transgenic mouse model of sustained IL-1 beta overexpression that was capable of driving robust neuroinflammation lasting months after transgene activation. This response was characterized by astrocytic and microglial activation in addition to induction of proinflammatory cytokines. Surprisingly, when triggered in the hippocampus of the APPswe/PS1dE9 mouse model of AD, 4 weeks of IL-1 beta overexpression led to a reduction in amyloid pathology. Congophilic plaque area fraction and frequency as well as insoluble amyloid beta 40 (A beta 40) and A beta 42 decreased significantly. These results demonstrate a possible adaptive role for IL-1 beta-driven neuroinflammation in AD and may help explain recent failures of antiinflammatory therapeutics for this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“previous studies demonstrated that IL1 overexpression enhances A clearance.9,53”
From CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse Models (2010) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is consistent with our previously published data showing that IL-1β does not influence Aβ production [4, 6, 7, 28].”
From IL-1β-driven amyloid plaque clearance is associated with an expansion of transcriptionally reprogrammed microglia (2019) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For amyloid pathology, there is data that activated micro/astroglia enhances Aβ phagocytosis [60, 62, 71]”
From Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways (2022) · cites this paper as [62]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies demonstrated that overexpression of IL1, an inflammatory cytokine leads to reduced A pathology in mouse models of AD. 9,53”
From CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse Models (2010) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Various genetically modified mouse models have convincingly demonstrated the role for other chemokines/cytokine pathways in altering the accumulation of mononuclear phagocytes (monocytes, macrophages, and microglia) and A pathology, including CCR2 59 and IL1.9”
From CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse Models (2010) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“numerous other studies have suggested that altering the proliferation, 58 signaling, 8,9,11 and migration 7,59 of microglia directly impact development of A pathology.”
From CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse Models (2010) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“As previously described [28], APP/PS1 mice transduced with rAAV2-IL-1β showed significant reductions in hippocampal amyloid plaques compared to mice treated with rAAV2-Phe, as determined by immunohistochemical (IHC) analysis using both 6E10 staining and MX04 (Fig. 1b)”
From IL-1β-driven amyloid plaque clearance is associated with an expansion of transcriptionally reprogrammed microglia (2019) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Hippocampal expression of IL-1β was shown to robustly reduce plaques in the APP/PS1 model and 3xTg-AD model but worsened tauopathy in the 3xTg-AD model [62, 63].”
From Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways (2022) · cites this paper as [62]
In the citing paper
“In turn, increased cytokines, such as interleukin-1, can influence Aβ uptake (Mrak and Griffin, 2000; Shaftel et al., 2007).”
From LC3-Associated Endocytosis Facilitates β-Amyloid Clearance and Mitigates Neurodegeneration in Murine Alzheimer’s Disease (2019) · cites this paper as Shaftel et al., 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus
Srinivas, S., Watanabe, T., Lin, C.-S., William, C. M., Tanabe, Y., Jessell, T. M., & Costantini, F. (2001) · BMC Developmental Biology · doi:10.1186/1471-213x-1-4 · Cited by 3,121
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
Simard, A. R., Soulet, D., Gowing, G., Julien, J.-P., & Rivest, S. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.022 · Cited by 1,265
Interleukin-1 and neuronal injury
Allan, S. M., Tyrrell, P. J., & Rothwell, N. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1664 · Cited by 992
Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease
Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W. K., Teter, B., Tran, T., Ubeda, O. J., Ashe, K. H., Frautschy, S. A., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05709.2000 · Cited by 876
McGeer, P. L., Itagaki, S., Tago, H., & McGeer, E. G. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90696-3 · Cited by 836
Co-expression of multiple transgenes in mouse CNS: a comparison of strategies
Jankowsky, J. L., Slunt, H. H., Ratovitski, T., Jenkins, N. A., Copeland, N. G., & Borchelt, D. R. (2001) · Biomolecular Engineering · doi:10.1016/s1389-0344(01)00067-3 · Cited by 746
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 427
Distinct cytokine profiles in human brains resilient to Alzheimer's pathology
Barroeta-Espar, I., Weinstock, L. D., Perez-Nievas, B. G., Meltzer, A. C., Siao Tick Chong, M., Amaral, A. C., Murray, M. E., Moulder, K. L., Morris, J. C., Cairns, N. J., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.10.009 · Cited by 133
Wu, M. D., Hein, A. M., Moravan, M. J., Shaftel, S. S., Olschowka, J. A., & O’Banion, M. K. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.09.012 · Cited by 134
Self-citationTargeting innate immunity for neurodegenerative disorders of the central nervous system
Andreasson, K. I., Bachstetter, A. D., Colonna, M., Ginhoux, F., Holmes, C., Lamb, B., Landreth, G., Lee, D. C., Low, D., Lynch, M. A., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13667 · Cited by 126
Self-citationPiirainen, S., Youssef, A. M., Song, C., Kalueff, A. V., Landreth, G. E., Malm, T., & Tian, L. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.01.046 · Cited by 130
Inflammatory mechanisms in neurodegeneration
Nichols, M. R., St‐Pierre, M., Wendeln, A., Makoni, N. J., Gouwens, L. K., Garrad, E. C., Sohrabi, M., Neher, J. J., Tremblay, M., & Combs, C. K. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14674 · Cited by 129
Interleukin-1β in Central Nervous System Injury and Repair.
Hewett, S. J., Jackman, N. A., & Claycomb, R. (2012) · PubMed · Cited by 121
Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease
Hickman, S. E., & Khoury, J. E. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791011982 · Cited by 120
Modulation of inflammation in transgenic models of Alzheimer’s disease
Birch, A. M., Katsouri, L., & Sastre, M. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-25 · Cited by 121
Lee, D. C., Ruiz, C. R., Lebson, L. A., Selenica, M. B., Rizer, J., Hunt, J. B., Rojiani, R., Reid, P., Kammath, S., Nash, K. R., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.014 · Cited by 122
Xu, J., & Ikezu, T. (2008) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-008-9136-0 · Cited by 120
Hippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo
Chakrabarty, P., Herring, A., Ceballos-Diaz, C., Das, P., & Golde, T. E. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-16 · Cited by 117
Cherif, A., Roelands, B., MEEUSEN, R. R., & Chamari, K. (2015) · Sports Medicine · doi:10.1007/s40279-015-0408-6 · Cited by 117
Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition
Chakrabarty, P., Tianbai, L., Herring, A., Ceballos-Diaz, C., Das, P., & Golde, T. E. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-36 · Cited by 116
Avila-Muñoz, E., & Arias, C. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.07.004 · Cited by 114
Assessing the contribution of inflammation in models of Alzheimer's disease
Johnston, H. R., Boutin, H., & Allan, S. M. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390886 · Cited by 114
Osteoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice
Kyrkanides, S., Tallents, R. H., Miller, J. H., Olschowka, M. E., Johnson, R. E., Yang, M., Olschowka, J. A., Brouxhon, S. M., & O’Banion, M. K. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-112 · Cited by 116
Self-citationInfection, systemic inflammation, and Alzheimer's disease
Lim, S., Rodríguez‐Ortiz, C. J., & Kitazawa, M. (2015) · Microbes and Infection · doi:10.1016/j.micinf.2015.04.004 · Cited by 117
Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy
Nash, K. R., Lee, D. C., Hunt, J. B., Morganti, J. M., Selenica, M.-L., Moran, P., Reid, P., Brownlow, M., Guang-Yu Yang, C., Savalia, M., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.011 · Cited by 108
Systemic and CNS Inflammation Crosstalk: Implications for Alzheimer’s Disease
Paouri, E., & Georgopoulos, S. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321154618 · Cited by 109
Macrophages in Alzheimer’s disease: the blood-borne identity
Gate, D., Rezai-Zadeh, K., Jodry, D., Rentsendorj, A., & Town, T. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0422-7 · Cited by 107
Eikelenboom, P., Hoozemans, J. J. M., Veerhuis, R., van Exel, E. R., Rozemüller, A. J. M., & van Gool, W. A. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt118 · Cited by 110
Telomere shortening reduces Alzheimer’s disease amyloid pathology in mice
Rolyan, H., Scheffold, A., Heinrich, A., Begus-Nahrmann, Y., Langkopf, B. H., Hölter, S. M., Vogt-Weisenhorn, D. M., Liss, B., Wurst, W., Lie, D. C., et al. (2011) · Brain · doi:10.1093/brain/awr133 · Cited by 106
Neuroinflammation in the Aging Down Syndrome Brain; Lessons from Alzheimer's Disease
Wilcock, D. M. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/170276 · Cited by 104
Microglial Activation in Alzheimers Disease
Schlachetzki, J. C. M., & Hüll, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509790147179 · Cited by 105
Mastrangelo, M. A., Sudol, K. L., Narrow, W. C., & Bowers, W. J. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090059 · Cited by 100
Gallagher, J. J., Minogue, A. M., & Lynch, M. A. (2012) · Neurodegenerative Diseases · doi:10.1159/000337458 · Cited by 99
ER stress activates immunosuppressive network: implications for aging and Alzheimer’s disease
Salminen, A., Kaarniranta, K., & Kauppinen, A. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01904-z · Cited by 99
Inflammation in transgenic mouse models of neurodegenerative disorders
Schwab, C., Klegeris, A., & McGeer, P. L. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.013 · Cited by 97
Guo, H.-S., Cheng, Y. F., Wu, J., Wang, C. M., Wang, H., Zhang, C., Qiu, Z. K., & Xu, J. P. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.058 · Cited by 97
Microglia responses to interleukin‐6 and type I interferons in neuroinflammatory disease
West, P. K., Viengkhou, B., Campbell, I. L., & Hofer, M. J. (2019) · Glia · doi:10.1002/glia.23634 · Cited by 101
Perspectives on neuroinflammation and excitotoxicity: A neurotoxic conspiracy?
Viviani, B., Boraso, M., Marchetti, N., & Marinovich, M. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.03.004 · Cited by 103
Montgomery, S. L., Mastrangelo, M. A., Habib, D., Narrow, W. C., Knowlden, S. A., Wright, T. W., & Bowers, W. J. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.001 · Cited by 96
Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain
Selenica, M. B., Alvarez, J. A., Nash, K. R., Lee, D. C., Cao, C., Lin, X., Reid, P., Mouton, P. R., Morgan, D., & Gordon, M. N. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-86 · Cited by 99
Microglia in Alzheimer's Disease: It's All About Context
Weitz, T. M., & Town, T. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/314185 · Cited by 95
“, 2007 [55] Mouse models Forcing brain IL-1β expression using IL-1βXAT transgenic mice activates “good” neuroinflammation and dramatically reduces amyloid plaque pathology in APP/PS1 mice.”
BackgroundTachida, Y., Nakagawa, K., Saito, T., Saido, T. C., Honda, T., Saito, Y., Murayama, S., Endo, T., Sakaguchi, G., Kato, A., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05127.x · Cited by 86
Gut-Brain Axis in the Early Postnatal Years of Life: A Developmental Perspective
Jena, A., Montoya, C. A., Mullaney, J. A., Dilger, R. N., Young, W., McNabb, W. C., & Roy, N. C. (2020) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2020.00044 · Cited by 98
Taepavarapruk, P., & Song, C. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06524.x · Cited by 92
Microglia and brain macrophages: An update
Sasaki, A. (2016) · Neuropathology · doi:10.1111/neup.12354 · Cited by 91
Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer's Disease
Griñán‐Ferré, C., Codony, S., Pujol, E., Yang, J., Leiva, R., Escolano, C., Puigoriol‐Illamola, D., Companys‐Alemany, J., Corpas, R., Sanfeliu, C., et al. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00854-1 · Cited by 99
Moore, A. H., Bigbee, M. J., Boynton, G. E., Wakeham, C. M., Rosenheim, H. M., Staral, C. J., Morrissey, J. L., & Hund, A. K. (2010) · Pharmaceuticals · doi:10.3390/ph3061812 · Cited by 90
Matousek, S. B., Ghosh, S., Shaftel, S. S., Kyrkanides, S., Olschowka, J. A., & O’Banion, M. K. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9331-2 · Cited by 86
“In an earlier study, we found that sustained elevation of IL- 1β leads to profound reduction in plaque pathology in APPswe/PS1dE9 mice on a mixed B6C3F1/J background (Shaftel et al. 2007a).”
InfluentialSelf-citationHoeijmakers, L., Heinen, Y., van Dam, A.-M., Lucassen, P. J., & Korosi, A. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00398 · Cited by 85
Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer’s disease
Cantarella, G., Benedetto, G. D., Puzzo, D., Privitera, L., Loreto, C., Saccone, S., Giunta, S., Palmeri, A., & Bernardini, R. (2014) · Brain · doi:10.1093/brain/awu318 · Cited by 87
Inflammasome assembly in neurodegenerative diseases
Singh, J., Habean, M. L., & Panicker, N. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.07.009 · Cited by 83
Poon, C., Shah, K., Lin, C., Tse, R., Kim, K. K., Mooney, S. J., Aubert, I., Stefanovic, B., & Hynynen, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-32250-3 · Cited by 83
Ben-Menachem-Zidon, O., Ben-Menahem, Y., Ben-Hur, T., & Yirmiya, R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.208 · Cited by 81
Valera, E., Ubhi, K. K., Mante, M., Rockenstein, E. M., & Masliah, E. (2013) · Glia · doi:10.1002/glia.22610 · Cited by 79
Shen, Z., Bao, X., & Wang, R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00314 · Cited by 77
Wu, M. D., Montgomery, S. L., Rivera‐Escalera, F., Olschowka, J. A., & O’Banion, M. K. (2013) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2013.03.003 · Cited by 80
Self-citationHe, Z., Yang, Y., Xing, Z., Zuo, Z., Wang, R., Gu, H., Qi, F., & Yao, Z. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2644-4 · Cited by 79
Neuroinflammatory Signaling in the Pathogenesis of Alzheimer’s Disease
Uddin, M. S., Kabir, M. T., Jalouli, M., Rahman, M. A., Jeandet, P., Behl, T., Alexiou, A. T., Albadrani, G. M., Abdel‐Daim, M. M., Perveen, A., et al. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210826130210 · Cited by 76
Cytokines in the Brain and Neuroinflammation: We Didn’t Starve the Fire!
Konsman, J. P. (2022) · Pharmaceuticals · doi:10.3390/ph15020140 · Cited by 81
Rivera-Escalera, F., Pinney, J. J., Owlett, L., Ahmed, H., Thakar, J., Olschowka, J. A., Elliott, M. R., & O’Banion, M. K. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1645-7 · Cited by 75
“In particular, we found that sustained hippocampal IL-1β expression decreases amyloid plaque accumulation in APPswe/PS1dE9 (APP/PS1) mice [4, 6] and in the”
Self-citationMcNamee, E. N., Griffin, É. W., Ryan, K. M., Ryan, K. J., Heffernan, S., Harkin, A., & Connor, T. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.03.014 · Cited by 75
Gray, S. C., Kinghorn, K. J., & Woodling, N. S. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.272571 · Cited by 76
Neuroinflammation in Alzheimer’s disease: Pleiotropic roles for cytokines and neuronal pentraxins
Swanson, A., Wolf, T., Sitzmann, A., & Willette, A. A. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.02.015 · Cited by 72
IL-1Ra and its Delivery Strategies: Inserting the Association in Perspective
Akash, M. S. H., Rehman, K., & Chen, S. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1118-0 · Cited by 74
Azizi, G., & Mirshafiey, A. (2012) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2012.705292 · Cited by 75
Targeting Microglia in Alzheimer’s Disease: Pathogenesis and Potential Therapeutic Strategies
Sun, Z., Zhang, X., So, K.-F., Jiang, W., & Chiu, K. (2024) · Biomolecules · doi:10.3390/biom14070833 · Cited by 71
Innate Immunity in Alzheimer’s Disease: A Complex Affair
Guillot‐Sestier, M., & Town, T. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312050008 · Cited by 72
Luís, J. P., Simões, C. J. V., & Brito, R. M. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031731 · Cited by 74
Kitic, M., Hochmeister, S., Wimmer, I., Bauer, J., Misu, T., Mader, S., Reindl, M., Fujihara, K., Lassmann, H., & Bradl, M. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-5 · Cited by 69
Cellular and Molecular Mediators of Neuroinflammation in Alzheimer Disease
Yang, S. (2019) · International Neurourology Journal · doi:10.5213/inj.1938184.092 · Cited by 72
Pourbadie, H. G., Sayyah, M., Khoshkholgh-Sima, B., Choopani, S., Nategh, M., Motamedi, F., & Shokrgozar, M. A. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.020 · Cited by 68
Page, A. Y. L., Garneau, H., Dupuis, G., Frost, E. H., Larbi, A., Witkowski, J. M., Pawelec, G., & Fülöp, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00783 · Cited by 67
Functional Aspects of Redox Control During Neuroinflammation
Rosales‐Corral, S., Reiter, R. J., Tan, D., Ortiz, G. G., & López-Armas, G. D. C. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2629 · Cited by 66
Activation of STAT3 Regulates Reactive Astrogliosis and Neuronal Death Induced by AβO Neurotoxicity
Toral-Ríos, D., Patiño‐López, G., Gómez‐Lira, G., Gutiérrez, R., Becerril-Pérez, F., Rosales-Córdova, A., León‐Contreras, J. C., Hernández‐Pando, R., León‐Rivera, I., Soto‐Cruz, I., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207458 · Cited by 63
Łabuzek, K., Liber, S., Gabryel, B., & Okopień, B. (2010) · Pharmacological Reports · doi:10.1016/s1734-1140(10)70343-1 · Cited by 64
Manji, Z., Rojas, A., Wang, W., Dingledine, R. J., Varvel, N. H., & Ganesh, T. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180678 · Cited by 65
Gallagher, J. J., Finnegan, M. E., Grehan, B., Dobson, J., Collingwood, J. F., & Lynch, M. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110614 · Cited by 64
Wu, J., Zhao, Y., & Deng, Z.-K. (2017) · Inflammopharmacology · doi:10.1007/s10787-017-0394-4 · Cited by 62
Inflammation and Microglia Actions in Alzheimer’s Disease
Combs, C. K. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9165-3 · Cited by 62
Aging, depression and dementia: The inflammatory process
Carrera-González, M. P., Cantón-Habas, V., & Rich‐Ruiz, M. (2022) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/149897 · Cited by 61
Corbett, G. T., Roy, A., & Pahan, K. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102624 · Cited by 54
Kyrkanides, S., Miller, A. W., Miller, J. H., Tallents, R. H., Brouxhon, S. M., Olschowka, M. E., O’Banion, M. K., & Olschowka, J. A. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.06.024 · Cited by 61
Self-citationLabarta-Bajo, L., & Allen, N. J. (2025) · Neuron · doi:10.1016/j.neuron.2024.12.010 · Cited by 62
Ajit, D., Woods, L. T., Camden, J. M., Thebeau, C. N., El-Sayed, F. G., Greeson, G. W., Erb, L., Petris, M. J., Miller, D. C., Sun, G. Y., et al. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8577-5 · Cited by 60
Wilcock, D. M., Zhao, Q., Morgan, D., Gordon, M. N., Everhart, A. L., Wilson, J. G., Lee, J. E., & Colton, C. A. (2011) · ASN NEURO · doi:10.1042/an20110018 · Cited by 60
Wang, D., Gao, K., Li, X., Shen, X., Zhang, X., Ma, C., Qin, C., & Zhang, L. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.03.013 · Cited by 59
Inflammatory Risk Factors and Pathologies Associated with Alzheimers Disease
Sastre, M., Richardson, J. C., Gentleman, S., & Brooks, D. J. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256062 · Cited by 59
Lee, D. C., Rizer, J., Hunt, J. B., Selenica, M. ‐. B., Gordon, M. N., & Morgan, D. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12002 · Cited by 57
Myeloid Cells in Alzheimer's Disease: Culprits, Victims or Innocent Bystanders?
Meyer‐Luehmann, M., & Prinz, M. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.08.011 · Cited by 58
Immunosurveillance as a regulator of tissue homeostasis
Senovilla, L., Galluzzi, L., Zitvogel, L., & Kroemer, G. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.06.005 · Cited by 57
Matousek, S. B., Hein, A. M., Shaftel, S. S., Olschowka, J. A., Kyrkanides, S., & O’Banion, M. K. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06759.x · Cited by 55
Self-citationKwon, H., Lee, E. H., Park, S., Park, J., Hong, J.-H., Kim, E., Shin, T.-S., Kim, Y., & Han, P. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01084-z · Cited by 56
Cawthorne, C., Prenant, C., Smigova, A., Julyan, P. J., Maroy, R., Herholz, K., Rothwell, N. J., & Boutin, H. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01068.x · Cited by 54
Neural stem/progenitor cells in Alzheimer's disease.
Tincer, G., Mashkaryan, V., Bhattarai, P., & Kızıl, Ç. (2016) · Europe PMC (PubMed Central) · Cited by 56
Koller, E. J., Brooks, M., Golde, T. E., Giasson, B. I., & Chakrabarty, P. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0142-z · Cited by 55
Owlett, L. D., Karaahmet, B., Le, L., Belcher, E. K., Dionisio-Santos, D. A., Olschowka, J. A., Elliott, M. R., & O’Banion, M. K. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02397-y · Cited by 53
Self-citationSustained Arginase 1 Expression Modulates Pathological Tau Deposits in a Mouse Model of Tauopathy
Hunt, J. B., Nash, K. R., Placides, D. S., Moran, P., Selenica, M. B., Abuqalbeen, F., Ratnasamy, K., Slouha, N., Ospina, S. R., Savlia, M., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.3959-14.2015 · Cited by 57
Increased tauopathy drives microglia-mediated clearance of beta-amyloid
Chen, W., Abud, E., Yeung, S. T., Lakatos, A., Nassi, T., Wang, J., Blum, D. L., Buée, L., Poon, W. W., & Blurton-Jones, M. M. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0336-1 · Cited by 54
Cytokine signaling convergence regulates the microglial state transition in Alzheimer’s disease
Lau, S., Fu, A. K. Y., & Ip, N. Y. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03810-0 · Cited by 55
Glucagon‐like peptide‐1 protects synaptic and learning functions from neuroinflammation in rodents
Iwai, T., Sawabe, T., Tanimitsu, K., Suzuki, M., Sasaki‐Hamada, S., & Oka, J. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23335 · Cited by 51
Yang, J. H., Lee, E. O., Kim, S. E., Suh, Y.-H., & Chong, Y. H. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.05.008 · Cited by 51
Targeting the Endocannabinoid System in Alzheimer's Disease
Koppel, J. L., & Davies, P. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15315 · Cited by 51
Weekman, E. M., Sudduth, T. L., Abner, E. L., Popa, G. J., Mendenhall, M. D., Brothers, H. M., Braun, K. J., Greenstein, A. W., & Wilcock, D. M. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-127 · Cited by 50
Michaud, J.-P., Richard, K. L., & Rivest, S. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-5 · Cited by 48
McFarland, K. N., & Chakrabarty, P. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01179-3 · Cited by 48
He, Y., Jackman, N. A., Thorn, T. L., Vought, V. E., & Hewett, S. J. (2015) · Glia · doi:10.1002/glia.22828 · Cited by 48
Endocannabinoid regulation of amyloid-induced neuroinflammation
Vázquez, C., Tolón, R. M., Grande, M. T., Caraza, M., Moreno, M., Koester, E. C., Villaescusa, B., Ruiz‐Valdepeñas, L., Fernández, J., Cravatt, B. F., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.003 · Cited by 50
Metadata
- Authors
- Shaftel, S. S., Kyrkanides, S., Olschowka, J. A., Miller, J.-N. H., Johnson, R. E., & O’Banion, M. K.
- Affiliations
- University of Rochester Medicine (US)
- Corresponding author
- O’Banion, M. Kerry
- Venue
- Journal of Clinical Investigation
- Published
- 2007-06-01
- Volume
- 117
- Issue
- 6
- Pages
- 1595-1604
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1878531
- OpenAlex
- W2105385589
- Cited by
- 433
- References
- 46
- Citations by year
- 2026: 8 · 2025: 25 · 2024: 16 · 2023: 18 · 2022: 34 · 2021: 22 · 2020: 20 · 2019: 26 · 2018: 23 · 2017: 20 · 2016: 18 · 2015: 24 · 2014: 32 · 2013: 26 · 2012: 35
- FWCI
- 12.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Rochester
- National Institutes of Health (14642)
- Medical Center, University of Rochester
- National Institute of General Medical Sciences (GM 07356, T32GM007356)
- National Institute of Neurological Disorders and Stroke (NS048522, R29NS033553, NS 33553, R21NS048522, R01NS033553)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- IL-1β, neuroinflammation, Alzheimer's disease, amyloid plaques, hippocampus, astrocyte activation, microglial activation, inflammatory cytokines, APPswe/PS1dE9 transgenic mice, amyloid-beta
- MeSH terms
- Alzheimer Disease, Animals, Base Sequence, Disease Models, Animal, Hippocampus, Humans, Inflammation, Mice, Transgenic, Nerve Degeneration, Recombinant Proteins, Gene Expression, Amyloid beta-Protein Precursor, DNA Primers, Mice, Interleukin-1beta, Presenilin-1, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
